Left to right: Kingson Lin, Kevin Rakin, Seth Herzon and Ranjit Bindra
July 28, 2022 03:14 PM EDTUpdated 04:29 PM
R&D

By ex­ploit­ing the DNA re­pair sys­tem, Yale sci­en­tists want to crack chemother­a­py re­sis­tant brain can­cer

Lei Lei Wu

News Reporter

In 2005, Roger Stupp pub­lished an ar­ti­cle in NE­JM, show­ing that adding temo­zolo­mide to ra­dio­ther­a­py ex­tend­ed brain can­cer pa­tients’ sur­vival time …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times